Sector Expert: Kevin DeGeeter

Ladenburg Thalmann

Image: Kevin DeGeeter

Kevin DeGeeter is a director at Ladenburg Thalmann & Co. Inc. He is responsible for equity research coverage of personalized medicine and medical device companies with market capitalizations between $50 million and $2 billion. His coverage focuses on molecular diagnostics and medical equipment used in oncology, cardiovascular disease and infectious disease, as well as related research markets. Prior to joining Ladenburg Thalmann he was an analyst at Oppenheimer & Co., with responsibility for small-cap molecular diagnostic and biotechnology stocks. He has 10 years of buyside and sellside research experience, including positions with J. P. Morgan, PaineWebber, Natexis Bleichroeder and Manning & Napier Advisors. DeGeeter received a bachelor's degree in economics from Colgate University.



Recent Quotes

"MESO is now well positioned to potentially conclude partnering discussions for MPC-06-ID in the coming months; we reiterate our Buy rating."

— Kevin DeGeeter, Ladenburg Thalmann (5/10/16)
more >

"New results increased our confidence in MESO's Phase 3 aGVHD study."

— Kevin DeGeeter, Ladenburg Thalmann (2/23/16)
more >

"We expect MSB, following restructuring, to be funded through fiscal Q4/17."

— Kevin DeGeeter, Ladenburg Thalmann (12/17/15)
more >

"Professor Joanne Kurtzberg discussed aGHVD treatments including MSB's."

— Kevin DeGeeter, Ladenburg Thalmann (12/8/15)
more >

"MSB's Phase 3 study in GvHD is likely to meet its primary endpoint."

— Kevin DeGeeter, Ladenburg Thalmann (12/4/15)
more >

"The first commercial launch should alter MSB's investment profile."

— Kevin DeGeeter, Ladenburg Thalmann (11/25/15)
more >

"MSB's Phase 2 study in rheumatoid arthritis is enrolling 48 patients."

— Kevin DeGeeter, Ladenburg Thalmann (11/24/15)
more >

"MSB announced Japan recommended approval of JR-031 for acute GvHD."

— Kevin DeGeeter, Ladenburg Thalmann (9/8/15)
more >



Due to permission requirements, not all quotes are shown.